KLTO (Klotho Neurosciences) Piotroski F-Score: N/A (As of Jun. 25, 2026)


KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Klotho Neurosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Klotho Neurosciences's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of Klotho Neurosciences was 3. The lowest was 3. And the median was 3.

Klotho Neurosciences  (NAS:KLTO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Klotho Neurosciences Piotroski F-Score Related Terms


Klotho Neurosciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Piotroski F-Score Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
N/A N/A N/A N/A

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 3.00 N/A

KLTO vs KTTA, JUNS, ZEOX: Piotroski F-Score Comparison

For the Biotechnology subindustry, Klotho Neurosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Piotroski F-Score falls into.


KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Sep24) TTM:
Net Income was -2.067 + -2.234 + -4.093 + -2.896 = $-11.29 Mil.
Cash Flow from Operations was -0.944 + -1.554 + -1.968 + -1.088 = $-5.55 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep24)
to the end of this year (Sep25) was
(2.464 + 2.457 + 2.987 + 10.846 + 10.073) / 5 = $5.7654 Mil.
Total Assets at the begining of this year (Sep24) was $2.46 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.77 Mil.
Total Current Liabilities was $0.09 Mil.
Net Income was -0.126 + -0.672 + -0.452 + -2.959 = $-4.21 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep23)
to the end of last year (Sep24) was
(0 + 2.193 + 0 + 3.309 + 2.464) / 5 = $2.65533333 Mil.
Total Assets at the begining of last year (Sep23) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.16 Mil.
Total Current Liabilities was $0.98 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Klotho Neurosciences's current Net Income (TTM) was -11.29. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Klotho Neurosciences's current Cash Flow from Operations (TTM) was -5.55. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep24)
=-11.29/2.464
=-4.58198052

ROA (Last Year)=Net Income/Total Assets (Sep23)
=-4.209/0
=

Klotho Neurosciences's return on assets of this year was -4.58198052. Klotho Neurosciences's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Klotho Neurosciences's current Net Income (TTM) was -11.29. Klotho Neurosciences's current Cash Flow from Operations (TTM) was -5.55. ==> -5.55 > -11.29 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep24 to Sep25
=0/5.7654
=0

Gearing (Last Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/2.65533333
=0

Klotho Neurosciences's gearing of this year was 0. Klotho Neurosciences's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep25)=Total Current Assets/Total Current Liabilities
=7.774/0.093
=83.59139785

Current Ratio (Last Year: Sep24)=Total Current Assets/Total Current Liabilities
=0.155/0.982
=0.15784114

Klotho Neurosciences's current ratio of this year was 83.59139785. Klotho Neurosciences's current ratio of last year was 0.15784114. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Klotho Neurosciences's number of shares in issue this year was 59.417. Klotho Neurosciences's number of shares in issue last year was 16.689. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Klotho Neurosciences's gross margin of this year was . Klotho Neurosciences's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep24)
=0/2.464
=0

Klotho Neurosciences's asset turnover of this year was 0. Klotho Neurosciences's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Klotho Neurosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.


Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price